Scarica l'app Stockscreener
308.68
0.31%
-0.95
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PODD Giù?
Forum
Previsione
Insulet Corporation Borsa (PODD) Ultime notizie
Insulet’s Q2 Beat Is Impressive, But The Elevated Valuation Makes The Stock A Hold (PODD) - Seeking Alpha
PODD Q2 Deep Dive: Omnipod 5 Adoption and International Expansion Drive Results - Yahoo Finance
Quant Strategy Flags Insulet Corporation for EntryJuly 2025 Patterns & Weekly Chart Analysis and Guides - 선데이타임즈
Insulet Q2 Earnings and Revenue Exceed Estimates, Stock Rises, Margins Improve - AInvest
Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise - Yahoo Finance
Insulet Corporation Reports Strong Q2 2025 Growth - MSN
Why Insulet (PODD) is a Top Growth Stock for the Long-Term - sharewise.com
Insulet Corp: Strong Financial Position and Competitive Strengths - AInvest
Why Insulet (PODD) Is Up 7.8% After Raising Full-Year Revenue Guidance on Omnipod Momentum - simplywall.st
Price Consolidation Hints at Upcoming Move in Insulet CorporationFast Exit and Entry Strategy Guide Offered - beatles.ru
Insulin pump makers Tandem and Insulet post contrasting Q2 results - MSN
Insulet's Insider Activity and Executive Compensation Transparency: A Governance and Investor Sentiment Analysis - AInvest
Insulet’s Earnings Call Highlights Robust Growth and Optimism - The Globe and Mail
Research Alert: CFRA Maintains Hold Opinion On Shares Of Insulet Corporation - 富途牛牛
RBC Capital Raises PT for Insulet to $350, Maintains Outperform Rating - AInvest
Insulet Corporation shares rise 2.61% intraday after multiple brokerages raised price targets. - AInvest
Insulet (PODD) Is Up 5.3% After Raising Full-Year Revenue Guidance on Strong Q2 Sales – Has The Bull Case Changed? - simplywall.st
Baird Adjusts Price Target on Insulet to $360 From $350, Maintains Outperform Rating - MarketScreener
Insulet stock price target raised to $350 from $330 at RBC Capital - Investing.com Canada
Bernstein raises Insulet stock price target to $400 on type 2 diabetes growth - Investing.com Nigeria
RBC Raises Price Target on Insulet to $350 From $330, Keeps Outperform Rating - MarketScreener
Insulet price target raised to $350 from $330 at RBC Capital - TipRanks
Insulet Corporation (PODD) PT Raised to $350 at RBC Capital - StreetInsider
Insulet Corporation (NASDAQ:PODD) Q2 2025 Earnings Call Transcript - Insider Monkey
Insulet Corporation (PODD) PT Raised to $400 at Bernstein SocGen Group - StreetInsider
Insulet price target raised to $353 from $331 at Canaccord - TipRanks
Morgan Stanley Raises Price Target on Insulet to $370 From $355, Keeps Overweight Rating - MarketScreener
Goldman Sachs Adjusts Price Target on Insulet to $399 From $380, Maintains Buy Rating - MarketScreener
Canaccord Genuity Adjusts Price Target on Insulet to $353 From $331, Maintains Buy Rating - MarketScreener
Bernstein Adjusts Price Target on Insulet to $400 From $375, Maintains Outperform Rating - MarketScreener
Tandem, Insulet monitoring CMS payment proposal for diabetes tech - Yahoo Finance
Insulet raises full-year 2025 revenue growth guidance to 24%-27% as Omnipod 5 drives global adoption - MSN
Insulet Corp (PODD) Q2 2025 Earnings Call Highlights: Record Revenue and Raised Guidance Amid ... By GuruFocus - Investing.com Canada
Insulet Corp. stock outperforms competitors on strong trading day - MSN
Insulet: Q2 Earnings Snapshot - Stamford Advocate
Insulet Corp. Q2 Profit Decreases, But Beats Estimates - Nasdaq
Canaccord Genuity raises Insulet stock price target to $353 on strong growth - Investing.com Nigeria
Insulet Corporation (PODD) PT Raised to $353 at Canaccord Genuity - StreetInsider
Insulet Ups The Pace Thanks To Demand For Its Wearable Pump - Finimize
Insulet’s Wearable Pumps Propel Earnings Past Wall Street Goals - Finimize
Leerink Partners Raises Price Target on Insulet to $339 From $333 - MarketScreener
Wells Fargo Adjusts Price Target on Insulet to $350 From $330, Maintains Overweight Rating - MarketScreener
Insulet (NASDAQ:PODD) Beats Expectations in Strong Q2, Stock Soars - Yahoo Finance
Insulet Peer Tandem Diabetes Underwhelming Earnings, Dull Outlook Drags Stock - Yahoo Finance
Jefferies raises Insulet stock price target to $375 on strong Q2 results - Investing.com Nigeria
Insulet Lifts Annual Forecast On Increased Adoption For Insulin Pump Omnipod 5 - inkl
Jefferies Adjusts Insulet Price Target to $375 From $360, Maintains Buy Rating - MarketScreener
Insulet Corporation (PODD) PT Raised to $375 at Jefferies - StreetInsider
Insulet Corp reports results for the quarter ended June 30Earnings Summary - TradingView
1.36%
0.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):